Encompass Health SVP Fay sells $1.27 million in stock By Investing.com

Encompass Health beat Q4 expectations with EPS of $1.46 vs $1.30 consensus (≈+12%), revenue of $1.54B in line, and adjusted EBITDA of $336.0M vs $313.2M consensus (≈+$22.8M). Management issued initial 2026 guidance above analyst forecasts and Raymond James and Truist reiterated Strong Buy/Buy with $130 and $140 price targets. SVP/Treasurer Edmund Fay sold 11,937 shares at $107 for $1,277,259, donated 3,000 shares, and now holds 86,325 shares; results were aided by increased supplemental payments and lower startup losses despite higher Oracle Fusion-related support costs.

Analysis

The market move around the two names creates a clear separation between credit/operational stress in concentrated consumer finance franchises and idiosyncratic operating leverage in asset-light healthcare providers. For the consumer-lending franchise, the primary second-order pain will be rising funding costs and forced asset-disposals that depress recovery values across auto and unsecured pools; that typically plays out over weeks for funding spreads and over 3–6 months for realized loss recognition and mark-to-market resets. For the healthcare operator, the more interesting lever is margin convergence once one-time implementation and start-up costs normalize—if supplemental cash flows remain durable, that convergence can drive mid-teens EBITDA expansion within 4–8 quarters without material revenue growth. A key crosscutting risk is policy volatility: payer adjustments or macro credit stress can flip both stories—one toward insolvency and the other toward a valuation reset—within a 3–12 month window depending on regulatory headlines or capital access events.

Key Decisions for Investors

• Short GSY.TO equity or buy 3-month ATM puts (target 50% move, stop-loss 25%); thesis: funding stress → mark-to-market and forced disposals over weeks; risk: rapid stabilization via emergency financing could cap upside.
• Long EHC via 9–12 month call spread (buy 12-month +10% ITM call, sell +30% OTM call) sized as 1–2% portfolio; target 25–40%+ return if margins re-rate as one-time rollout costs ebb; downside limited to premium paid—buy protective puts if policy headlines spike.
• Pair trade: long EHC / short ORCL (equal notional) for 3–6 months to isolate operational recovery and hedge vendor-execution noise; reward: capture healthcare multiple expansion while offsetting tech-rollout execution risk; risk: ORCL outperformance or EHC policy reversal.
• De-risk exposure to Canadian specialty finance names—avoid adding new long positions and prefer liquid hedges (index CDS or sector ETF shorts) for 1–3 month horizon to protect against spillover funding shocks; reward: protects capital if contagion widens, cost is ongoing carry.